Filing Flows › Alamar Biosciences (ALMR) › Guidance history
Alamar Biosciences (ALMR) guidance history: what it guided and what it reported
Alamar Biosciences gave guidance in 3 earnings releases on file since Aug 10, 2026. Its releases raised guidance once and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $116M–$120M (Aug 10, 2026) → raised $121M–$123M (Nov 3, 2026) | — | to be reported | — |
Stock-based compensation
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $13.0M–$15.0M (Nov 4, 2026) | — | to be reported | — |
The latest quarter
Alamar Biosciences, Q3 2026: revenue $33.5M (+68% year over year), operating margin -45.1%, net loss $13.3M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
Questions
Does Alamar Biosciences beat its guidance?
Alamar Biosciences gave guidance in 3 earnings releases on file since Aug 10, 2026. Its releases raised guidance once and lowered it 0 times.
How often does Alamar Biosciences raise guidance?
Its earnings releases raised guidance once and lowered it 0 times since Aug 10, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.